date:Jun 25, 2014
ims to boost sales to $25 billion by 2025 from $14.69 billion in 2013.
TAX TREATMENT
The tax aspect of Monsanto's potential deal with Syngenta appears to have been similar to that of U.S. drugmaker Pfizer's failed attempt to buy rival AstraZeneca for nearly 70 billion pounds ($119.06 billion) last month.
That deal would have allowed Pfizer to reincorporate in Britain and pay a significantly lower corporate tax. The U.S. company would also have been able to use tens of billions of dollars it h